GLG News by Physicians who Treat Depression (US)

When varenicline (Chantix) first became available for use in patients, I was incredibly impressed by how effective it was.  I had one patient who was so addicted to cigarette smoking that he could not sleep through the night without a smoke--he would awake every hour or two and then go back to...

No good data that Chantix is associated with suicide Need more controlled research to answer questions Scary adverse events are not the same as side effects directly linked to medication

Doxepin was developed as an antidepressant nearly 40 years ago.  It has been used by generations of psychiatrists for its sedating and sleep promoting actions, much as many other of the sedating antidepressants of yore.  Now it is being developed as a treatment of insomnia--the one twist is...

Somaxon Pharmaceuticals has submitted a NDA for Silenor for the treatment of insomnia.  The active ingredient is doxepin, which has been available for years.The effect of the drug can be expected to be very modest, side effects unfavorable when compared to Ambien or Lunesta, and with both significant...

This article is important primarily to those companies and reps who do not pay attention.  Doctors are human and will be most pleased to see those reps who comply with the physician's stated needs.  If the days or hours are limited or an appointment required, the reps need to stay within those...

What is the best way to market pharmaceutical and other medical products to physicians? There is certainly bias among some physicians against the pharmaceutical industry. It is felt by many that industry sponsored research studies are invalid and will always show the products in a favorable light. On...

Outcomes in patients implanted with the artificial disc compare favorably with single level ACDF after 2 years.

MAOI's really work very well in patients in whom tricyclic and newer and safer variations of the theme (blockade of norepinephrine, serotonin, and dopamine uptake) do not.  It is about time that the focus has shifted to a safer version of MAOIs, the selective and reversible novel class of drugs...

Insurance company data is primitive and flawed. Any entity that can manage this data well in the future will be extremely profitable.

Xenoport's trial for XP13512 in restless legs syndrome (RLS) shows strongly positive 9 month data in second phase 3  trial, should be a major win in the marketplace.  RLS represent a major unmet need, for drugs with sustained efficacy and high tolerability.